Navigation Links
Nastech Pharmaceutical Company Announces Promotion of Rick Costantino, Ph.D., to Chief Scientific Officer of Delivery
Date:10/4/2007

BOTHELL, Wash., Oct. 4 /PRNewswire-FirstCall/ -- Nastech Pharmaceutical Company Inc. (Nasdaq: NSTK) announced today the promotion of Henry "Rick" Costantino, Ph.D., to Chief Scientific Officer of Delivery. Dr. Costantino will assume the responsibilities for leading Nastech's development of new drug delivery technologies for peptide and protein therapeutics. Paul Johnson, Ph.D., Nastech's Chief Scientific Officer since 2003, is retiring tomorrow, October 5, 2007, as was previously announced.

"Nastech continues to rapidly advance new technologies for the development of non-invasive delivery options for peptide and protein therapeutics," stated Steven C. Quay, M.D., Ph.D., Chairman, President and CEO of Nastech. "Rick's promotion ensures that we will maintain strong scientific leadership and continuity in our research efforts as we expand our capabilities in this area. He will concentrate on advancing the development of new drugs and delivery systems for peptide and protein drugs."

Dr. Quay added, "I would like to thank Dr. Johnson for his many years of dedicated service to Nastech. During his tenure as Chief Scientific Officer, Nastech's drug delivery technologies have made significant advances. We wish Paul well in his future endeavors."

"As Chief Scientific Officer of Delivery, I am pleased to have the opportunity to direct the outstanding pharmaceutical development team here at Nastech to develop new approaches for the delivery of peptide and protein drugs," stated Dr. Costantino. "My experience in the drug delivery industry and at Nastech provides the background to support our goals as we further the advancement of Nastech's drug delivery technologies, providing more opportunities for patients and physicians while increasing shareholder value."

Dr. Costantino has served as Director of Formulations since June 2003 and was recently promoted to Vice President of Pharmaceutical Research & Development. Prior to joining Nastech, he spent five years at Alkermes, Inc. working to develop new technologies for enhanced delivery of peptide and protein therapeutics and served as a key member in managing external collaborations. Prior to that, he spent three years at Genentech, Inc. as a research scientist in their pharmaceutical research and development group. Dr. Costantino received his Bachelor of Science and Master of Science degree from The Johns Hopkins University and a Ph.D. in Chemical Engineering from the Massachusetts Institute of Technology.

In Dr. Costantino's new role, he will focus on the development of intranasal peptides and proteins. The Company's RNAi therapeutics programs will continue under the direction of Dr. Quay.

About Nastech

Nastech is a biopharmaceutical company developing innovative products based on proprietary molecular biology-based drug delivery technologies. Nastech and its collaboration partners are developing products for multiple therapeutic areas including osteoporosis, obesity, diabetes, autism, respiratory diseases and inflammatory conditions. Additional information about Nastech is available at http://www.nastech.com.

Nastech Forward Looking Statements

Statements made in this press release may be forward-looking statements within the meaning of Federal Securities laws that are subject to certain risks and uncertainties and involve factors that may cause actual results to differ materially from those projected or suggested. Factors that could cause actual results to differ materially from those in forward-looking statements include, but are not limited to: (i) the ability of Nastech to obtain additional funding; (ii) the ability of Nastech to attract and/or maintain manufacturing, research, development and commercialization partners; (iii) Nastech's and/or a partner's ability to successfully complete product research and development, including preclinical and clinical studies and commercialization; (iv) Nastech's and/or a partner's ability to obtain required governmental approvals; and (v) Nastech's and/or a partner's ability to develop and commercialize products that can compete favorably with those of competitors. Additional factors that could cause actual results to differ materially from those projected or suggested in any forward-looking statements are contained in Nastech's most recent periodic reports on Form 10-K and Form 10-Q that are filed with the Securities and Exchange Commission. Nastech assumes no obligation to update and supplement forward-looking statements because of subsequent events.

Contacts:

Nastech

Ed Bell

Director, Investor Relations

(425) 908-3639

ir@nastech.com

Russo Partners LLC

Matthew Haines (Investors/Media)

(212) 845-4235


'/>"/>
SOURCE Nastech Pharmaceutical Company Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. South Africa Wins landmark case against pharmaceutical giants
2. Pharmaceutical giant offers AIDS related antifungal drug free to 50 countries
3. Pharmaceutical giant offers AIDS related antifungal drug free to 50 countries
4. Setting up a new pharmaceutical industry in India
5. Medicis Pharmaceutical company enters pediatric market
6. Supply of Radiopharmaceuticals Hampered by Attacks
7. Pharmaceutical companies are targeting patients
8. FDA approves Watson Pharmaceuticals Oxytrol patch
9. Ranbaxy Pharmaceuticals Inc awarded the prestigious outstanding supplier award received from Wal-Mart
10. Indian Pharmaceutical Industries Stops Manufacturing And Sale Of Valdecoxib
11. Pharmaceutical industries grant for R&D to be monitored
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2017)... ... April 28, 2017 , ... Ushio ... These lamps offer an instant energy-saving solution for F32T8 fluorescent lamps on most ... disconnect ballasts. These 50,000 hour rated lamps utilize the existing electronic ballast, saving ...
(Date:4/28/2017)... , ... April 28, 2017 , ... ... been previously exposed to more adverse experiences than children in the general population. ... such as abuse, neglect or other family challenges. While no fault of their ...
(Date:4/28/2017)... (PRWEB) , ... April 28, 2017 , ... ... or hERG liability could substantially improve drug safety and minimize the cost of ... for validating ion channel inhibition using cell lines and for cardiac toxicity using ...
(Date:4/28/2017)... ... ... Overseer at The House of Yahweh in Abilene, Texas, has published a new post that ... Yisrayl says with so many titles and names for the Creator, it’s hard for many ... Scripture, backed with a lot of research, the truth is undeniable. , “If you ...
(Date:4/28/2017)... ... ... Intellitec Solutions announced the publication of a case study ... solution that integrates to their PointClickCare EHR software package. With the guidance of ... now has the capability to achieve its goal for a comprehensive EHR solution, ...
Breaking Medicine News(10 mins):
(Date:4/20/2017)...  CVS Pharmacy, the retail division of CVS ... design to enhance the retail customer experience with ... and expanded beauty selections paired with informational signage ... offerings. Together with its innovative digital programs, these ... experience at CVS Pharmacy.  "Pharmacy ...
(Date:4/20/2017)... Research and Markets has announced the ... Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies ... ... was valued at US$ 7,167.6 Mn in 2015, and is ... a CAGR of 5.6% from 2016 to 2024. ...
(Date:4/20/2017)... 2017 Research and Markets has announced ... Services Market Analysis By Service (Manufacturing, Research), By Country, (Brazil, ... 2025" report to their offering. ... The Latin American pharmaceutical contract manufacturing services ... Low drug registration cost in Latin American countries ...
Breaking Medicine Technology: